Adalimumab Treatment in Pediatric-Onset Crohn's Disease Patients after Infliximab Failure: A Single Center Study
| Autor: | Yon Ho Choe, Won Jae Song, So Yoon Choi, Ben Kang |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2016 |
| Předmět: |
musculoskeletal diseases
medicine.medical_specialty Pediatric Crohn's disease Antibody to infliximab Disease Single Center 03 medical and health sciences Antibodies to infliximab 0302 clinical medicine Internal medicine medicine Adalimumab skin and connective tissue diseases Hepatology business.industry Gastroenterology digestive system diseases Infliximab humanities stomatognathic diseases Pediatric onset Crohn's disease 030220 oncology & carcinogenesis Pediatrics Perinatology and Child Health 030211 gastroenterology & hepatology Original Article business medicine.drug |
| Zdroj: | Pediatric Gastroenterology, Hepatology & Nutrition |
| ISSN: | 2234-8840 2234-8646 |
| Popis: | Purpose We aimed to investigate the efficacy and safety of adalimumab in pediatric-onset Crohn's disease patients who had failed treatment with infliximab. Methods In this retrospective study, patients included were those who had been diagnosed with Crohn's disease before 18 years old, and had received treatment with adalimumab after infliximab failure. The efficacy of adalimumab treatment was investigated at 1 month and 1 year, and adverse events that had occurred during treatment with adalimumab were explored. Results Ten patients were included in this study. The median duration from diagnosis to adalimumab treatment was 5.5 years (range: 2.4-7.9 years). At 1 month after adalimumab initiation, 80% (8/10) of patients showed clinical response, and 40% (4/10) achieved clinical remission. At 1 year, 71% (5/7) of patients showed clinical response, and 43% (3/7) were under clinical remission. Among the total included patients, 5 patients (50%) showed clinical response at 1 year. Primary non-response to adalimumab was observed in 2 patients (20%), and secondary failure to adalimumab was observed in 3 patients (30%) during 1 year treatment with adalimumab. No serious adverse event had occurred during adalimumab treatment. Conclusion Adalimumab was effective for 1 year without serious adverse events in half of pediatric-onset Crohn's disease patients who had failed treatment with infliximab. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|